TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Intrexon Corp (NYSE: XON) Investor Securities Class Action Lawsuit 05/03/2016

  • If you purchased shares of Intrexon Corp (NYSE: XON), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Intrexon Corp
Security
NYSE: XON

Case Name
Intrexon Shareholder Class Action Lawsuit 05/03/2016
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the Northern District of California

Class Period Begin
Class Period End
Deadline To File for Lead
You must register or login to receive notifications.

Click here to subscribe to Intrexon Corp.
Summary

April 26, 2017 - The complaint was not amended within 30 days. The case was dismissed.

February 24, 2017 - The court granted the defendants' motion to dismiss. The plaintiffs were given leave to amend the complaint within 30 days.

November 17, 2016 - A motion to dismiss the amended complaint was filed.

September 22, 2016 - An amended complaints filed.

May 3, 2016 - An investor in shares of Intrexon Corp (NYSE: XON) filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Intrexon Corp in connection with certain allegedly false and misleading statements made between May 12, 2015 and April 20, 2016.

According to the complaint the plaintiff alleges on behalf of purchasers of Intrexon Corp (NYSE: XON) common shares between May 12, 2015 and April 20, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 12, 2015 and April 20, 2016 the defendants issued false and misleading financial statements to investors.

On April 21, 2016, a report was published on Intrexon Corp asserting, among other things, that Intrexon Corp’s technology has recently been questioned by high-ranking officials from the WHO, CDC and NIH, that Intrexon Corp overstated revenues by 50% through transactions with related parties, that Intrexon Corp’s technology platform is an overhyped, undifferentiated collection of commodity and failed products, and that Intrexon Corp is the Theranos of the public markets.